cancer chemotherapy

Semustine, a DNA alkylating agent, is a cancer chemotherapy compound that is nephrotoxic in patients with malignant melanoma receiving adjuvant chemotherapy for the adjuvant treatment of leukemia.

Itasetron (U 98079A) is a 5-hydroxytryptamine 3-receptor antagonist used to prevent age-related memory deficits in rats.Itasetron's antiemetic activity in animal models of cancer chemotherapy and radiation therapy may be useful in the study of amnesia.

Endothall is a protein phosphatase 2A (PP2A) inhibitor, capable of inhibiting PP2A (IC50: 90 nM) and PP1 (IC50: 5 uM). It acts as a herbicide and can also be useful in cancer chemotherapy.

Nonabine is a compound with strong antiemetic properties that can be used to prevent nausea and vomiting associated with cancer chemotherapy.

Etoposide (VP-16-213) is a topoisomerase II inhibitor that inhibits DNA synthesis by forming a complex with topoisomerase II and DNA (IC50=60.3 μM). Etoposide has antitumor activity and induces apoptosis and autophagy.

Granisetron hydrochloride (Granisetron HCl) is a serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic for cancer chemotherapy patients.

Ethyl gallate (gallic acid ethyl ester) obviously decreases cell proliferation in MDA-MB-231 and MCF-7 cells in a dose- and time-dependent manner, exhibits cytotoxicity in a dose-dependent manner. Ethyl gallate can inhibit the abilities of invasion of breast cancer in vitro by inhibiting the mRNA levels of MMP-9 MMP-2, phosphorylation of Akt and protein expression of NF-κB and inhibits hydrogen peroxide signaling, may represent an alternative class of vasopressors for use in septic shock. Also, Ethyl gallate suppresses proliferation and invasion in human breast cancer cells by modulating the PI3K Akt pathway, which may contribute to inhibiting their downstream targets such as NF-κB p-65, Bcl-2 Bax, and mRNA levels of MMP-2 and MMP-9 in breast cancer cells, could be used as potential antioxidants with safe therapeutic application in cancer chemotherapy.

D-Fructose-1,6-bisphosphate sodium salt hydrate is the intermediate in carbohydrate metabolism, including glycolysis and gluconeogenesis. During glycolysis, it is produced by phosphorylation of fructose-6-phosphate by phosphofructokinase. The reverse reaction mediated by fructose-1, 6-diphosphatase-1 is one of the rate-limiting steps of gluconeogenesis. The same reaction occurs in the chloroplasts of plants, D-Fructose-1,6-bisphosphate sodium salt hydrate as part of the reducing pentose phosphate cycle. Since cancer cells use glycolysis as a primary source of metabolic energy production, this pathway has become a major target for cancer chemotherapy.

Levoleucovorin Calcium (CL307782), a calcium salt of the folinic acid, is used in cancer chemotherapy as an adjuvant.

Ondansetron hydrochloride (Zofran) is a serotonin 5-HT3 receptor antagonist, used to prevent nausea and vomiting caused by cancer chemotherapy, and radiation therapy.

Arvanil (N-Vanillylarachidonamide) is a synthetic capsaicin-amphetamine hybrid and a ligand for vanilloid receptor 1 (VR1) and cannabinoid receptor 1 (CB1), exhibiting neuroprotective activity, inhibiting spasm, and enhancing cisplatin chemotherapy sensitivity by inducing ferroptosis in HCC cells in vivo. It induces ferroptosis in liver cancer cells via binding to MICU1.

1-Deazaadenosine, a potent Adenosine deaminase inhibitor (Ki: 0.66 μM), exhibits anti-cancer activities in vitro and holds potential as a chemotherapy agent for lymphoproliferative disorders.

AG-1478 (NSC-693255) (Tyrphostin AG-1478) is a selective EGFR inhibitor.

KSI-3716 is a c-Myc inhibitor used as a bladder chemotherapy agent. It blocks the formation of the c-MYC MAX complex with the target gene promoter and induces cell cycle arrest and apoptosis. It can be used for bladder cancer research.

Ondansetron hydrochloride dihydrate (GR 38032) is a competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

LY2090314, an effective GSK-3α β inhibitor (IC50: 1.5 nM 0.9 nM), may improve the efficacy of platinum-based chemotherapy regimens. LY2090314 has been used in trials studying the treatment of Leukemia, Advanced Cancer, and Pancreatic Cancer.

Dimesna (BNP-778), when used in conjunction with active cancer chemotherapy agents, can reduce the toxicity associated with uremia.

Batanopride (originally named BMY-25801) is a 5-HT3 receptor antagonist that has been utilized in research to address vomiting in cancer patients undergoing chemotherapy.

SNI-1 inhibits the interaction between NEMO and CARP-1, enhancing the sensitivity of cancer cells to chemotherapy.

Efaproxiral (RSR13) is a hemoglobin allosteric modifier, a potential radiosensitizer and chemotherapy enhancer in cancer treatment, improving tumor oxygenation.

DC_AC50 is a dual inhibitor of Atox1 and CCS (copper chaperones), aimed at reducing or preventing acquired chemotherapy resistance by inhibiting intracellular copper chaperones. It binds to Atox1 and CCS, thereby reducing cancer cell proliferation and tumor growth.

Cephalomannine (Baccatin III) is a taxol derivative obtained from Taxus yunnanensis with antitumor activity.

CPI-455 is a specific KDM5 inhibitor with IC50 value of 10 ± 1 nM for full-length KDM5A in enzymatic assays, elevating global levels of H3K4 trimethylation (H3K4me3) and decreased the number of DTPs in multiple cancer cell line models treated with target

Granisetron, a serotonin receptor (5HT-3 selective) antagonist, is used as an antinauseant and antiemetic for cancer chemotherapy.